A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Barbara Davis Center
Outpatient CTRC
University of Colorado Hospital
Study ID
Protocol Number: 19-1748
More information available at ClinicalTrials.gov: NCT03978520
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers